Maternal and neonatal outcomes in obstetric antiphospholipid syndrome: a retrospective case-control study

产科抗磷脂综合征的母婴结局:一项回顾性病例对照研究

阅读:1

Abstract

OBJECTIVE: The combination of low-dose aspirin (LDA) and low-molecular-weight heparin (LMWH) is the standard of care for obstetric antiphospholipid syndrome (OAPS), significantly improving live birth rates. However, whether this regimen fully normalizes the pregnancy course and mitigates risks for both the mother and the neonate remains unclear. This study aimed to systematically evaluate whether significant maternal and neonatal morbidity persists in OAPS patients despite successful treatment and live birth. METHODS: This retrospective cohort study included 256 OAPS patients, including 166 criteria OAPS patients (C-OAPS-patients who fulfilled both the clinical and laboratory criteria of the Sydney criteria) and 90 non-criteria OAPS patients (NC-OAPS-patients who fulfilled only the clinical or only the laboratory criteria of the Sydney criteria) who achieved live birth, along with 768 matched healthy controls. We compared basic characteristics, laboratory parameters, and perinatal outcomes between the groups. RESULTS: Compared to healthy controls (n = 768), treated OAPS patients (n = 256) exhibited a persistent hypercoagulable state (elevated D-dimer and fibrin degradation product (FDP), p < 0.01) and a higher incidence of anemia (p < 0.001). Their neonates had significantly lower birth weight (p = 0.006) and elevated risks of neonatal infection (adjusted OR = 3.12, p = 0.004) and hyperbilirubinemia (adjusted OR = 2.06, p = 0.024), with the infection risk remaining significant in full-term infants. A subgroup analysis revealed no significant differences in obstetric history, maternal complications, comorbidities, and outcomes between the C-OAPS and NC-OAPS groups. CONCLUSION: Despite standard treatment, OAPS patients who deliver successfully remain at an increased risk for persistent maternal hypercoagulability and adverse neonatal outcomes. These findings underscore the need for a paradigm shift in management-from merely ensuring live birth to safeguarding neonatal health through proactive, multidisciplinary perinatal care.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。